Long Run Wealth Advisors LLC Grows Stock Holdings in GSK plc (NYSE:GSK)

Long Run Wealth Advisors LLC raised its position in shares of GSK plc (NYSE:GSK) by 23.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 106,278 shares of the pharmaceutical company’s stock after purchasing an additional 20,355 shares during the period. Long Run Wealth Advisors LLC’s holdings in GSK were worth $3,594,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. AQR Capital Management LLC increased its holdings in shares of GSK by 103.4% in the second quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock worth $1,015,000 after buying an additional 13,403 shares during the period. SG Americas Securities LLC increased its holdings in shares of GSK by 167.3% in the third quarter. SG Americas Securities LLC now owns 18,773 shares of the pharmaceutical company’s stock worth $767,000 after buying an additional 11,749 shares during the period. Diversified Trust Co purchased a new position in GSK during the 3rd quarter valued at about $308,000. Fulton Bank N.A. purchased a new position in GSK during the 3rd quarter valued at about $391,000. Finally, Aprio Wealth Management LLC purchased a new position in GSK during the 3rd quarter valued at about $202,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

Shares of GSK opened at $37.67 on Thursday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The business’s 50 day moving average price is $34.10 and its 200-day moving average price is $37.60. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The stock has a market cap of $78.07 billion, a P/E ratio of 24.46, a P/E/G ratio of 1.38 and a beta of 0.64.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. Equities research analysts anticipate that GSK plc will post 3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GSK. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GSK presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.